NASDAQ:ALQA - Alliqua Biomedical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.05 -0.07 (-3.30 %)
(As of 06/22/2018 03:37 AM ET)
Previous Close$2.12
Today's Range$2.0230 - $2.12
52-Week Range$1.58 - $4.60
Volume4,737 shs
Average Volume60,961 shs
Market Capitalization$9.96 million
P/E Ratio-0.32
Dividend YieldN/A
Beta0.94
Alliqua Biomedical logoAlliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies. It also provides contract manufacturing services, including the development, manufacture, and marketing of high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Yardley, Pennsylvania.

Receive ALQA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALQA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALQA
CUSIPN/A
Phone215-702-8550

Debt

Debt-to-Equity RatioN/A
Current Ratio0.36
Quick Ratio0.28

Price-To-Earnings

Trailing P/E Ratio-0.32
Forward P/E Ratio0.40
P/E GrowthN/A

Sales & Book Value

Annual Sales$19.57 million
Price / Sales0.52
Cash FlowN/A
Price / CashN/A
Book Value$3.14 per share
Price / Book0.65

Profitability

EPS (Most Recent Fiscal Year)($6.49)
Net Income$-25,700,000.00
Net Margins-114.41%
Return on Equity-122.50%
Return on Assets-63.67%

Miscellaneous

Employees60
Outstanding Shares5,010,000

Alliqua Biomedical (NASDAQ:ALQA) Frequently Asked Questions

What is Alliqua Biomedical's stock symbol?

Alliqua Biomedical trades on the NASDAQ under the ticker symbol "ALQA."

When did Alliqua Biomedical's stock split? How did Alliqua Biomedical's stock split work?

Alliqua Biomedical's stock reverse split before market open on Friday, October 6th 2017. The 1-10 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Alliqua Biomedical stock prior to the reverse split would have 10 shares after the split.

How were Alliqua Biomedical's earnings last quarter?

Alliqua Biomedical Inc (NASDAQ:ALQA) announced its earnings results on Tuesday, August, 9th. The company reported $0.50 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($2.70) by $3.20. The company earned $5.50 million during the quarter, compared to analysts' expectations of $5.38 million. Alliqua Biomedical had a negative net margin of 114.41% and a negative return on equity of 122.50%. View Alliqua Biomedical's Earnings History.

What price target have analysts set for ALQA?

1 brokerages have issued twelve-month price targets for Alliqua Biomedical's shares. Their forecasts range from $2.80 to $2.80. On average, they anticipate Alliqua Biomedical's stock price to reach $2.80 in the next year. View Analyst Ratings for Alliqua Biomedical.

Who are some of Alliqua Biomedical's key competitors?

Who are Alliqua Biomedical's key executives?

Alliqua Biomedical's management team includes the folowing people:
  • Mr. David Ian Johnson, CEO, Pres & Director (Age 60)
  • Mr. Bradford C. Barton, Chief Operating Officer (Age 58)
  • Mr. Pellegrino Pionati, Chief Strategy & Marketing Officer (Age 60)
  • Dr. Phillip D. Forman M.D., DPM, Exec. VP of Clinical Affairs (Age 59)
  • Dr. Janice M. Smiell M.D., Chief Medical Officer

Has Alliqua Biomedical been receiving favorable news coverage?

News stories about ALQA stock have been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alliqua Biomedical earned a daily sentiment score of 0.23 on Accern's scale. They also gave media coverage about the company an impact score of 46.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Alliqua Biomedical?

Shares of ALQA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alliqua Biomedical's stock price today?

One share of ALQA stock can currently be purchased for approximately $2.05.

How big of a company is Alliqua Biomedical?

Alliqua Biomedical has a market capitalization of $9.96 million and generates $19.57 million in revenue each year. The company earns $-25,700,000.00 in net income (profit) each year or ($6.49) on an earnings per share basis. Alliqua Biomedical employs 60 workers across the globe.

How can I contact Alliqua Biomedical?

Alliqua Biomedical's mailing address is 2150 CABOT BLVD WEST SUITE B, LANGHORNE PA, 19047. The company can be reached via phone at 215-702-8550 or via email at [email protected]


MarketBeat Community Rating for Alliqua Biomedical (ALQA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  379
MarketBeat's community ratings are surveys of what our community members think about Alliqua Biomedical and other stocks. Vote "Outperform" if you believe ALQA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALQA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.